Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist...

Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020 Norwood, MA, June ...

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results Topline results for Phase 3 study in systemic sclerosis on schedule for summer of 2020 followed by Phase 2b study results in cystic fibrosis Completed $46 million public offering in February...

Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock Norwood, MA, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...